Please login to the form below

Not currently logged in
Email:
Password:

Chiesi

This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases’s monthly treatment PRX-102 has demonstrated positive top-line results in a phase 3 trial evaluating the therapy in Fabry disease. ... Earlier this month, Protalix and Chiesi announced final

Latest news

  • Moderna inks R&D agreements with Vertex and Chiesi Moderna inks R&D agreements with Vertex and Chiesi

    Moderna has agreed to separate deals with Vertex and Chiesi for research and development spanning cystic fibrosis (CF) therapies and pulmonary arterial hypertension (PAH). ... Prior to announcing the Vertex deal, Moderna revealed that it had come to a

  • Chiesi launches new rare disease R&D division Chiesi launches new rare disease R&D division

    Chiesi acquired Lamzede when it bought Zymenex in 2013 – the drug is administered weekly as intravenous infusions and the works by replacing the missing or malfunctioning enzyme. ... identify opportunities for us to collaborate in research and patient

  • AZ builds case for its COPD triple as it chases GSK’s Trelegy AZ builds case for its COPD triple as it chases GSK’s Trelegy

    First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy is dosed just once per ... day. Privately-held company Chiesi doesn’t

  • Europe responding to gene therapy challenge, but picture remains fragmented Europe responding to gene therapy challenge, but picture remains fragmented

    Chiesi’s Holoclar is another groundbreaking ATMP, a stem cell replacement therapy for patients with the rare blindness condition limbal stem cell deficiency, which gained European approval in 2015. ... Giorgio Iotti, head of programme leadership and

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy and PT010 are dosed just

More from news
Approximately 16 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    GSK, AZ and Chiesi are each playing in this new market.

  • Deal Watch May 2016 Deal Watch May 2016

    911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.

  • Anticipating the future in healthcare Anticipating the future in healthcare

    The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not

  • Pharma deals during October 2012 Pharma deals during October 2012

    In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics